Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access

Health Affairs

Volumn 34, Issue 3, 2015, Pages 484-492

  Rutkow, Lainie ^a   Turner, Lydia ^a   Lucas, Eleanor ^a   Hwang, Catherine ^a,b   Caleb Alexander, G ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDUSTRY; DRUG MONITORING; FACE VALIDITY; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INFORMATION RETRIEVAL; INTERNAL MEDICINE; INTERNIST; MALE; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE; TEACHING HOSPITAL; AWARENESS; CROSS-SECTIONAL STUDY; MIDDLE AGED; PROCEDURES; PROGRAM EVALUATION; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

ADULT; ANALGESICS, OPIOID; AWARENESS; CROSS-SECTIONAL STUDIES; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S ROLE; PHYSICIANS, PRIMARY CARE; PROGRAM EVALUATION; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84924559818     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1085     Document Type: Article

References (46)

1. Worley J. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research. Issues Ment Health Nurs. 2012;33(5):319-28.
2. Fornili K, Simoni-Wastila L. Prescription monitoring programs: striking the balance between medical use and diversion. J Addict Nurs. 2011;22(1-2):77-82.
3. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21):1981-5.
4. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9): 618-27.
5. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401-35.
6. Coleman JJ. The supply chain of medicinal controlled substances: addressing the Achilles heel of drug diversion. J Pain Palliat Care Pharmacother. 2012;26(3):233-50.
7. Berge KH, Dillon KR, Sikkink KM, Taylor TK, Lanier WL. Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention. Mayo Clin Proc. 2012;87(7):674-82.
8. Alexander GC, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA. 2012; 308(18):1865-6.
9. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, et al. How does use of a prescription monitoring program change medical practice? Pain Med. 2012;13(10): 1314-23.
10. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41-51.
11. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3):434-42.
12. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5): 747-54.
13. Prescription Drug Monitoring Program Training and Technical Assistance Center. Status of prescription drug monitoring programs (PDMPs) [Internet]. Waltham (MA): The Center; 2014 Dec 19 [cited 2015 Jan 15]. Available from: http://www.pdmpassist.org/pdf/PDMPProgramStatus2014.pdf
14. Feldman L, Williams KS, Coates J, Knox M. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother. 2011; 25(4):313-7.
15. Fleming ML, Hatfield MD, Wattana MK, Todd KH. Exploratory study of emergency physicians' use of a prescription monitoring program using a framework of technology acceptance. J Pain Palliat Care Pharmacother. 2014;28(1):19-27.
16. Gershman JA, Gershman JA, Fass AD, Popovici I. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool. Pain Med. 2014; 15(12):2013-9.
17. Irvine JM, Hallvik SE, Hildebran C, Marino M, Beran T, Deyo RA.Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain. 2014;15(7):747-55.
18. Perrone J, DeRoos FJ, Nelson LS. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012. J Med Toxicol. 2012; 8(4):341-52.
19. American Medical Association. AMA Physician Masterfile [Internet]. Chicago (IL): AMA; [cited 2015 Jan 16]. Available from: http://www.ama-assn.org/ama/pub/aboutama/physician-data-resources/physician-masterfile.page
20. To access the Appendix, click on the Appendix link in the box to the right of the article online.
21. Dillman DA. Mail and telephone surveys: the total design method. New York (NY): John Wiley and Sons; 1978.
22. American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. Revised. [Internet]. Deerfield (IL): AAPOR; 2011 [cited 2015 Jan 16]. Available from: http://www.esomar.org/uploads/public/knowledge-and-standards/codesand-guidelines/ESOMAR_Standard-Definitions-Final-Dispositions-of-Case-Codes-and-Outcome-Rates-for-Surveys.pdf
23. Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA. 2012;307(17): 1805-6.
24. Clark T, Eadie J, Knue P, Kreiner P, Strickler G. Prescription drug monitoring programs [Internet]. Waltham (MA): Brandeis University, Prescription Drug Monitoring Program Center of Excellence; 2012 Sep 20 [cited 2015 Jan 16]. Available from: http://www.pdmpexcellence.org/sites/all/pdfs/Brandeis_PDMP_Report.pdf
25. Drug Enforcement Administration, Office of Diversion Control. State prescription drug monitoring programs [Internet]. Springfield (VA): The Office; [updated 2011 Oct; cited 2015 Jan 16]. Available from: http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm#4
26. Rolfs RT, Johnson E, Williams NJ, Sundwall DN. Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother. 2010;24(3):219-35.
27. New York City Department of Health and Mental Hygiene. Preventing misuse of prescription opioid drugs. City Health Information [serial on the Internet]. 2011 Dec [cited 2015 Jan 16]. Available from: http://www.nyc.gov/html/doh/downloads/pdf/chi/chi30-4.pdf
28. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2-guidance. Pain Physician. 2012;15(3 Suppl):S67-116.
29. Finklea K, Sacco LN, Bagalman E. Prescription drug monitoring programs [Internet]. Washington (DC): Congressional Research Service; 2014 Mar 24 [cited 2014 Sep 6]. Available from: http://fas.org/sgp/crs/misc/R42593.pdf
30. Thomas CP, Kim M, Nikitin RV, Kreiner P, Clark TW, Carrow GM. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. Pharmacoepidemiol Drug Saf. 2014;23(9):950-7.
31. Perrone J, Nelson LS. Medication reconciliation for controlled substances- an "ideal" prescriptiondrug monitoring program. N Engl J Med. 2012;366(25):2341-3.
32. Center for Managing Chronic Disease. Chronic disease statistics [Internet]. Ann Arbor (MI): University of Michigan; c2011 [cited 2014 Sep 6]. Available from: http://cmcd.sph.umich.edu/statistics.html
33. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011 [Internet]. Parsippany (NJ): The Institute; 2012 Apr [cited 2014 Sep 6]. Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf
34. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348(16):1556-64.
35. Wakeman SE, Baggett MV, Pham-Kanter G, Campbell EG. Internal medicine residents' training in substance use disorders: a survey of the quality of instruction and residents' self-perceived preparedness to diagnose and treat addiction. Subst Abus. 2013;34(4):363-70.
36. American Academy of Family Physicians. Pain management and opioid abuse: a public health concern [Internet]. Leawood (KS): AAFP; 2012 Jul [cited 2015 Jan 16]. (Position Paper). Available from: http://www.aafp.org/dam/AAFP/documents/patient_care/pain_management/opioid-abuse-position-paper.pdf
37. Kirschner N, Ginsburg J, Sulmasy LS. Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med. 2014; 160(3):198.
38. Brownson RC, Colditz GA, Proctor EK, editors. Dissemination and implementation research in health: translating science to practice. Oxford: Oxford University Press; 2012.
39. National Alliance for Model State Drug Laws. States that allow practitioners to designate an authorized agent to access the PMP database [Internet]. Charlottesville (VA): NAMSDL; c2014 [cited 2015 Jan 16]. Available from: http://www.namsdl.org/library/40B632AC-1372-636C-DD71B8182B3341FA/
40. Prescription Drug Abuse and Health Information Technology Work Group. Action plan for improving access to prescription drug monitoring programs through health information technology [Internet]. Washington (DC): Department of Health and Human Services; 2011 Jun 30 [cited 2014 Sep 6]. Available from: http://www.healthit.gov/sites/default/files/rules-regulation/063012-final-action-plan-clearance.pdf
41. Abedtash H, Finnell JT. A pilot study: integrating an emergency department with Indiana's prescription drug monitoring program. In: Stephanidis C, Antona M, editors. Universal access in human-computer interaction. New York (NY): Springer; 2013. p. 419-25.
42. Prescription Drug Monitoring Program Center of Excellence. PDMPs and Third Party Payers meeting, December 2012: report of proceedings [Internet]. Waltham (MA): Brandeis University; 2014 Apr [cited 2015 Jan 16]. Available from: http://www.pdmpexcellence.org/sites/all/pdfs/Brandeis_COE_PDMP_3rd_pty_payer_mtg_rpt.pdf
43. Prescription Drug Monitoring Program Center of Excellence. Mandating PDMP participation by medical providers: current status and experience in Kentucky [Internet]. Waltham (MA): Brandeis University; 2013 Nov [cited 2014 Sep 6]. (COE Briefing). Available from: http://www.pdmpexcellence.org/sites/all/pdfs/COE%20briefing%20on%20mandates%2011%2014%2013.pdf
44. Tennessee Department of Health. Frequently asked questions: Controlled Substance Monitoring Database (CSMD) and Prescription Safety Act [Internet]. Nashville (TN): The Department; [revised 2014 Dec 16; cited 2015 Jan 16]. Available from: http://health.state.tn.us/boards/Controlledsubstance/faq.shtml
45. Kentucky Cabinet for Health and Family Services. Per 1000 oxymorphone usage: Q4 2012 [Internet]. Frankfort (KY): CHFS; [cited 2014 Sep 6]. Available from: http://www.chfs.ky.gov/NR/rdonlyres/12F90847-46BB-4AD5-9ABB-19FA10C2AF79/0/KASPERQuarterlyTrendReportQ42012.pdf
46. Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Prescription drug abuse: a national survey of primary care physicians. JAMA Intern Med. 2014 Dec 8. [E-pub ahead of print].